A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 106 participants.
Also called NCT06218290
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 106 participants
- Sponsor
- Unicycive Therapeutics, Inc
- Registry
-
NCT06218290
-
- Other papers using this trial's data
- Two-Way Randomized Crossover Study to Establish Pharmacodynamic Bioequivalence Between Oxylanthanum Carbonate and Lanthanum Carbonate
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT06218290. Allocation not applicable; no masking; primary purpose treatment. Start 2023-12-15 (actual); primary completion 2024-05-29 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Assess the Tolerability of Oxylanthanum Carbonate in Patients With Chronic Kidney Disease on Dialysis
- Condition
- Chronic Kidney Disease Requiring Chronic Dialysis
- Intervention (Drug)
- Oxylanthanum Carbonate
- Lead sponsor
- Unicycive Therapeutics, Inc
Record details
- Record id
cardio:ct-nct06218290- Content hash
4fbfcb2e87b507ff4ad9496c720d5b911cd0fef95de2d31003a918b14e249c2f